Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization

Martínez-Lobo, Francisco Javier; Díez-Fuertes, Francisco; Simarro, I.; Castro, José María Albertos; Prieto, C.

doi:10.1016/j.vaccine.2011.07.076

Cited by 65 publications

(86 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The breadth of neutralization observed here was unexpected due to the widespread perception that PRRSV elicits specific immunity to the same or equivalent viruses, but not to unrelated viruses (Kim et al, 2007;Martinez-Lobo et al, 2011). Consistent with our findings, a recent study demonstrated PRRSV cross-neutralization of a genotype 1 virus with genotype 2 antisera (Binjawadagi et al, 2014).…”

Section: Discussionsupporting

confidence: 91%

“…While 50% titers are numerically higher than 90% titers, the FFN results shown in Table 1 are exceptional. Previously, reported neutralizing titers using FFN-type assays were consistently low (≤16), or undetectable (Binjawadagi et al, 2014;Kim et al, 2007;Li et al, 2014;Martinez-Lobo et al, 2011;Molina et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

“…PRRSV comprises two genotypic families, type 1 and type 2, that cause a prolonged infection of pigs, and show variable ability to induce neutralizing antibody responses (Martinez-Lobo et al, 2011). The two distinct genotypes share less than 60% nucleotide sequence similarity, and are only weakly immunologically cross-reactive (Murtaugh et al, 1995;Nelsen et al, 1999;Wensvoort et al, 1992).…”

Section: Q2mentioning

confidence: 99%

See 2 more Smart Citations

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus

Robinson

Nelson

et al. 2015

Virus Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Q2mentioning

confidence: 99%

See 1 more Smart Citation

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus

Robinson

Nelson

et al. 2015

Virus Research

View full text Add to dashboard Cite

“…The genetic differences however (usually expressed as ORF5 similarities) between the immunizing and the challenging strains cannot predict the degree of the protective immunity conferred [18]. Moreover marked differences have been observed among PRRSV isolates both in terms of their susceptibility to neutralization by NAs induced by other strains and also in their ability to induce NAs that are neutralizing a broad spectrum of isolates [26]. …”

Section: Discussionmentioning

confidence: 99%

Vaccination of piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX® EU provides protection against heterologous field challenge in the face of homologous maternally derived antibodies

Balka

Dreckmann

Papp³

et al. 2016

Porc Health Manag

View full text Add to dashboard Cite

BackgroundDue to difficulties in eradicating porcine reproductive and respiratory syndrome (PRRS) linked to biosecurity challenges, transmission of the virus and the lack of efficient DIVA vaccines, successful control of PRRS requires a combination of strict management measures and vaccination of both sows and piglets. The present study aimed to assess the efficacy of a recently developed MLV vaccine (Ingelvac PRRSFLEX® EU) in piglets at 2 and 3-weeks of age in the presence of homologous maternally derived antibodies as the dams were vaccinated with the same vaccine strain (ReproCyc® PRRS EU).MethodsThe study was carried out on a Hungarian farrow to finish farm naturally infected with PRRSv. The study was designed as a blind, placebo controlled side by side trial. ORF5 sequence similarity of the vaccine strain and the resident field strain was 87.8 %. PRRS specific real-time quantitative PCR was performed from serum samples to measure both the viral load and the frequency of virus positive animals.ResultsAt the time of the natural infection observed in the control group at 10–12 weeks of age, the number of viraemic animals did not increase significantly in the vaccinated group. To understand the infection dynamics, positive PCR samples with low Ct values were sequenced (ORF5) and the data analysis indicated the circulation of wild type virus in both groups, however wild type virus was only found in non-vaccinated animals.ConclusionsOur data indicate that piglets vaccinated at as early as 2 weeks of age with Ingelvac PRRSFLEX® EU were protected both in terms of proportion of viraemic animals and viraemia levels. It has to be highlighted that these results were achieved in piglets with high levels of homologous maternally derived antibodies (MDA) at the time of vaccination.

show abstract

“…During PRRSV infection, the induction of neutralizing antibodies indicates that the virus has begun to be cleared from the tissues and blood. Previous studies showed that the GP3 protein of European strains has a neutralizing epitope between amino acids 57 and 73 [39]; however, the detailed protein structure and function require further study. The data presented here showed that GP3 and GP5 could induce neutralizing antibodies in mice; however, the GP3 neutralizing antibody titer was low.…”

Section: Discussionmentioning

confidence: 99%

Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus

Ren

Sun

et al. 2014

BMC Vet Res

View full text Add to dashboard Cite

BackgroundThe European (EU) genotype of porcine reproductive and respiratory syndrome virus (Genotype-I PRRSV) has recently emerged in China. The coexistence of Genotype-I and -II PRRSV strains could cause seriously affect PRRSV diagnosis and management. Current vaccines are not able to protect against PRRSV infection completely and have inherent drawbacks. Thus, genetically engineered vaccines, including DNA vaccine and live vector engineered vaccines, have been developed. This study aimed to determine the enhanced immune responses of mice inoculated with a DNA vaccine coexpressing GP3 and GP5 of a Genotype-I PRRSV.ResultsTo evaluate the immunogenicity of GP3 and GP5 proteins from European-type PRRSV, three DNA vaccines, pVAX1-EU-ORF3-ORF5, pVAX1-EU-ORF3 and pVAX1-EU-ORF5, were constructed, which were based on a Genotype-I LV strain (GenBank ID: M96262). BALB/c mice were immunized with the DNA vaccines; delivered in the form of chitosan-DNA nanoparticles. To increase the efficiency of the vaccine, Quil A (Quillaja) was used as an adjuvant. GP3 and GP5-specific antibodies, neutralizing antibodies and cytokines (IL-2, IL-4, IL-10 and IFN gamma) from the immunized mice sera, and other immune parameters, were examined, including T-cell proliferation responses and subgroups of spleen T-lymphocytes. The results showed that ORF3 and ORF5 proteins of Genotype-I PRRSV induced GP3 and GP5-specific antibodies that could neutralize the virus. The levels of Cytokines IL-2, IL-4, IL-10, and IFN–γ of the experimental groups were significantly higher than those of control groups after booster vaccination (P < 0.05). The production of CD3+CD4+ and CD3+CD8+ T lymphocyte was also induced. T lymphocyte proliferation assays showed that the PRRSV LV strain virus could stimulate the proliferation of T lymphocytes in mice in the experimental group.ConclusionsUsing Quil A as adjuvant, Genotype-I PRRSV GP3 and GP5 proteins produced good immunogenicity and reactivity. More importantly, better PRRSV-specific neutralizing antibody titers and cell-mediated immune responses were observed in mice immunized with the DNA vaccine co-expressing GP3 and GP5 proteins than in mice immunized with a DNA vaccine expressing either protein singly. The results of this study demonstrated that co-immunization with GP3 and GP5 produced a better immune response in mice.

show abstract

Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization

Cited by 65 publications

References 47 publications

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus

Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus

Vaccination of piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX® EU provides protection against heterologous field challenge in the face of homologous maternally derived antibodies

Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus

Contact Info

Product

Resources

About